A federal judge has dismissed a lawsuit by a New York family who claimed the Department of Defense misled Americans into ...
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...
A federal judge in Washington D.C. cited the government’s “general immunity” in dismissing a lawsuit that accused the ...
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...
Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines. Read more about PFE stock here.
Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.
BioNTech's updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus.